First-in-Human Trial of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine with Adjuvant of Aluminum Hydroxide and CpG 1018

Szu-Min Hsieh; Wang-Da Liu; Yu-Shan Huang; Yi-Jiun Lin; Erh-Fang Hsieh; Wei-Cheng Lian; Charles Chen; I-Chen Tai; Shan-Chwen Chang.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21254668

Documentos relacionados

  1. Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study.
  2. Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study.
  3. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
  4. [Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years].
  5. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
  6. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
  7. The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants.
  8. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
  9. Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.
  10. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8<sup>+</sup> T cell responses post SARS-CoV-2 infection.